Subscribe
shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
29 August 2019GenericsRory O'Neill

Delhi court approves Natco generic of Novartis cancer drug

The Delhi High Court has cleared the way for a generic version of Novartis’ small-cell lung cancer drug Ceritinib, after the Swiss pharmaceutical company’s patent was revoked.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis takes aim at Indian drug companies over Entresto generics
29 October 2019   Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
Asia
Pfizer fights approval of generic Ibrance
21 October 2021   Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
Biotechnology
NextCure targeted in cancer drug trade secrets suit
16 December 2021   Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Novartis takes aim at Indian drug companies over Entresto generics
29 October 2019   Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
Asia
Pfizer fights approval of generic Ibrance
21 October 2021   Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
Biotechnology
NextCure targeted in cancer drug trade secrets suit
16 December 2021   Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.

More on this story

Americas
Novartis takes aim at Indian drug companies over Entresto generics
29 October 2019   Swiss pharmaceutical company Novartis has filed a patent infringement lawsuit against three Indian rivals in a US federal court over proposed generics of its heart failure drug Entresto.
Asia
Pfizer fights approval of generic Ibrance
21 October 2021   Pfizer is seeking to block a generic version of its cancer drug Ibrance from entering the market until the patent covering the drug expires in May 2036.
Biotechnology
NextCure targeted in cancer drug trade secrets suit
16 December 2021   Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility